Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681508 | 0.88 | P2RX4 (0.58) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL2680566 | 0.85 | P2RX4 (0.60) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL18661904 | 0.84 | P2RX4 (0.60) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL16239089 | 0.83 | P2RX4 (0.61) | P2RX4KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL16239231 | 0.83 | P2RX4 (0.50) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL2681057 | 0.83 | P2RX4 (0.50) | P2RX4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23094055 | 0.81 | P2RX4 (0.50) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL2681079 | 0.80 | P2RX4 (0.57) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL2680821 | 0.79 | P2RX4 (0.57) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL16812979 | 0.79 | CHRM4 (0.59) | P2RX4ALDH1A1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2716302-B1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | UNIV KYUSHU (JP) | 2017-09-27 | — | — | EP | claimed |
| US-20100256123-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-10-07 | — | — | US | claimed |
| EP-2058304-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2009-05-13 | — | — | EP | claimed |
| US-20230059381-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | UNIV KYUSHU (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20190046539-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | UNIV KYUSHU (JP) | 2019-02-14 | — | — | US | disclosed |
| EP-2716302-B1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | UNIV KYUSHU (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170065608-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | UNIV KYUSHU (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3132803-A2 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | Kyushu University (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9561235-B2 | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | KYUSHU UNIVERSITY (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20150328231-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | UNIV KYUSHU (JP) | 2015-11-19 | — | — | US | disclosed |
| US-9115123-B2 | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | KYUSHU UNIVERSITY (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140163013-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | NIPPON CHEMIPHAR CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-20140148599-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2636414-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | Kyushu University (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-20120116073-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR COL, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20100256123-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2058304-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328231-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | P2RX5, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 3399/4885TUBB4A 3727/4885 |
| US-20100256123-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX1, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 954/4885TUBB4A 3167/4885 |
| US-20230059381-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | P2RX5, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 2522/4885TUBB4A 3509/4885 |
| US-20140163013-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | P2RX5, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 2567/4885TUBB4A 3507/4885 |
| US-20170065608-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | P2RX5, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 2567/4885TUBB4A 3507/4885 |
| US-20140148599-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | P2RX5, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 3399/4885TUBB4A 3727/4885 |
| US-20120116073-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX1, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 954/4885TUBB4A 3167/4885 |
| US-20190046539-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | P2RX5, P2RX3, P2RX4 | P2RX4 3/4885ALDH1A1 2567/4885TUBB4A 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.